HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

GRL 02031

a protease inhibitor with anti-HIV1 activity; structure in first source

Also Known As:

GRL-02031; GRL02031

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133

Experts

1.	Amano, Masayuki: 1 article (03/2009)
2.	Das, Debananda: 1 article (03/2009)
3.	Ghosh, Arun K: 1 article (03/2009)
4.	Koh, Yasuhiro: 1 article (03/2009)
5.	Leschenko, Sofiya: 1 article (03/2009)
6.	Mitsuya, Hiroaki: 1 article (03/2009)
7.	Nakata, Hirotomo: 1 article (03/2009)
8.	Nakayama, Maki: 1 article (03/2009)
9.	Ogata-Aoki, Hiromi: 1 article (03/2009)

Related Diseases

1.

03/01/2009 - "The present data warrant the further development of GRL-02031 as a potential therapeutic agent for the treatment of infections with primary and multidrug-resistant HIV-1 variants."
03/01/2009 - "GRL-02031 at relatively low concentrations blocked the infection and replication of each of the HIV-1(NL4-3) variants exposed to and selected by up to 5 microM of saquinavir, amprenavir, indinavir, nelfinavir, or ritonavir and 1 microM of lopinavir or atazanavir (EC(50) range, 0.036 to 0.14 microM). "

Related Drugs and Biologics

1.	Lopinavir
2.	Nelfinavir (Viracept)
3.	Indinavir (Crixivan)
4.	Ritonavir (Norvir)
5.	Saquinavir (Invirase)
6.	Atazanavir Sulfate (Reyataz)
7.	amprenavir (Agenerase)